↓ Skip to main content

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Overview of attention for book
Attention for Chapter 5: The Microenvironment of Lung Cancer and Therapeutic Implications.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
The Microenvironment of Lung Cancer and Therapeutic Implications.
Chapter number 5
Book title
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Published in
Advances in experimental medicine and biology, December 2015
DOI 10.1007/978-3-319-24932-2_5
Pubmed ID
Book ISBNs
978-3-31-924931-5, 978-3-31-924932-2
Authors

Mittal, Vivek, El Rayes, Tina, Narula, Navneet, McGraw, Timothy E, Altorki, Nasser K, Barcellos-Hoff, Mary Helen, Vivek Mittal, Tina El Rayes, Navneet Narula, Timothy E. McGraw, Nasser K Altorki, Mary Helen Barcellos-Hoff, McGraw, Timothy E.

Editors

Aamir Ahmad, Shirish M. Gadgeel

Abstract

The tumor microenvironment (TME) represents a milieu that enables tumor cells to acquire the hallmarks of cancer. The TME is heterogeneous in composition and consists of cellular components, growth factors, proteases, and extracellular matrix. Concerted interactions between genetically altered tumor cells and genetically stable intratumoral stromal cells result in an "activated/reprogramed" stroma that promotes carcinogenesis by contributing to inflammation, immune suppression, therapeutic resistance, and generating premetastatic niches that support the initiation and establishment of distant metastasis. The lungs present a unique milieu in which tumors progress in collusion with the TME, as evidenced by regions of aberrant angiogenesis, acidosis and hypoxia. Inflammation plays an important role in the pathogenesis of lung cancer, and pulmonary disorders in lung cancer patients such as chronic obstructive pulmonary disease (COPD) and emphysema, constitute comorbid conditions and are independent risk factors for lung cancer. The TME also contributes to immune suppression, induces epithelial-to-mesenchymal transition (EMT) and diminishes efficacy of chemotherapies. Thus, the TME has begun to emerge as the "Achilles heel" of the disease, and constitutes an attractive target for anti-cancer therapy. Drugs targeting the components of the TME are making their way into clinical trials. Here, we will focus on recent advances and emerging concepts regarding the intriguing role of the TME in lung cancer progression, and discuss future directions in the context of novel diagnostic and therapeutic opportunities.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 1%
Unknown 68 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 20%
Student > Ph. D. Student 13 19%
Student > Master 9 13%
Researcher 6 9%
Student > Doctoral Student 5 7%
Other 11 16%
Unknown 11 16%
Readers by discipline Count As %
Medicine and Dentistry 23 33%
Biochemistry, Genetics and Molecular Biology 10 14%
Agricultural and Biological Sciences 5 7%
Engineering 4 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 11 16%
Unknown 13 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2016.
All research outputs
#5,389,999
of 7,469,749 outputs
Outputs from Advances in experimental medicine and biology
#1,196
of 2,124 outputs
Outputs of similar age
#191,661
of 303,723 outputs
Outputs of similar age from Advances in experimental medicine and biology
#290
of 557 outputs
Altmetric has tracked 7,469,749 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,124 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 303,723 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 557 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.